HBVtech

Perpetuu Biosciences (formerly HBVtech) is a pre-clinical stage biotechnology company focused on developing transformative gene therapies for serious and persistent viral infections. The company's proprietary in vivo adeno-associated virus (AAV) platform is designed to deliver therapeutic antibody genes directly into skeletal muscle cells, enabling sustained, long-term endogenous expression of neutralizing antibodies from a single injection. Perpetuu's pipeline features two co-lead programs: HBVZ10, a potentially curative gene therapy for chronic hepatitis B virus (HBV) infection, and CMVZ01, a long-acting prophylactic therapy for cytomegalovirus (CMV) in high-risk transplant recipients. By maintaining high antibody levels over time, the platform aims to continuously block viral spread and reservoir replenishment, offering a practical path toward durable functional cures.